ATRIUM THERAPEUTICS INC

RNANASDAQ

🏆 #2778 by market capEarnings Aug 13US Equity

$626.30▼ $44.78 (−7.15%)

Simulated price

1h—

24h▼ 7.2%

7d—

14d—

30d—

1y—

🏦Market Cap

$210M

Small Cap

📈Revenue Growth (YoY)

+22.0%

Healthy

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

5.5x

Fair

Otter Score

Weak

No chart data available for RNA.

Trading Snapshot

Day Range: $616.58 – $633.11
52-Week Range: $11.13 – $73.06
Volume: $5.71B
Avg Volume: $4.84B
Shares Outstanding: 17.1M
Next Earnings: Sep 28, 2026

Fundamentals Snapshot

Annual Revenue: $19M
Last Q Revenue: $20M
P/E Ratio: —
P/S Ratio: 5.5x
EPS (TTM): $-3.86
Dividend Yield: —

Why Investors Own RNA

✓High-growth profile — revenue up +28.8% YoY with expanding US Equity exposure.
✓Healthy economics — 27% gross margin and 7% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$19M▲ +24.9% YoY

Gross Margin (TTM)

26.8%▲ +2.9% YoY

Operating Income (TTM)

$4M▲ +24.9% YoY

Free Cash Flow (TTM)

$1M▲ +24.9% YoY

About ATRIUM THERAPEUTICS INC

Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.

🦦